Daniil StroyakovskiyMoscow City Oncology Hospital, Russia
Characteristics of Patients with a Complete Response Treated with Dabrafenib plus Trametinib Combination Therapy: Findings from Pooled COMBI-d and COMBI-v 5-Year Analysis
Caroline Robert, MD, PhD, Jean-Jacques Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, MD, Evgeny Levchenko, Vanna Chiarion Sileni, MD, Jacob Schachter, MD, Claus Garbe, Igor Bondarenko, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, MD, Dirk Schadendorf, MD, Georgina V. Long, MD, PhD
November 13, 2020 | November 2020 Vol 11, No 11
Two large phase 3 studies (COMBI-d [NCT01584648] and COMBI-v [NCT01597908]) evaluated the efficacy and safety of oral dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (D+T) as first-line therapy in patients (pts) with BRAF V600E- or V600K-mutant unresectable or metastatic cutaneous melanoma.
Last modified: November 13, 2020